Thioguanine administered as a continuous intravenous infusion to pediatric patients is metabolized to the novel metabolite 8-hydroxy- thioguanine

Journal of Pharmacology and Experimental Therapeutics

Volumn 291, Issue 2, 1999, Pages 870-874

  Kitchen, Brenda J ^a,b   Moser, Asher ^a   Lowe, Elizabeth ^a   Balis, Frank M ^a   Widemann, Brigitte ^a   Anderson, Lawrence ^a,c   Strong, John ^a,c   Blaney, Susan M ^a,d   Berg, Stacey L ^a,d   O'Brien, Michelle ^a   Adamson, Peter C ^a,e  

^a NATIONAL CANCER INSTITUTE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^d TEXAS CHILDREN S CANCER CENTER   (United States)

^e CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE OXIDASE; ANTIMETABOLITE; DRUG METABOLITE; MERCAPTOPURINE; THIOGUANINE DERIVATIVE; TIOGUANINE;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; DRUG ELIMINATION; DRUG METABOLISM; DRUG STRUCTURE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MASS SPECTROMETRY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; ULTRAVIOLET SPECTROSCOPY;

ALDEHYDE OXIDASE; ALDEHYDE OXIDOREDUCTASES; ANTIMETABOLITES, ANTINEOPLASTIC; CHILD; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HUMANS; INFUSIONS, INTRAVENOUS; MASS SPECTROMETRY; THIOGUANINE;

EID: 0032747650     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Adamson PC, Balis FM, Arndt CA, Holcenberg JS, Narang PK, Murphy RF, Gillespie AJ and Poplack DG (1991) Intrathecal 6-mercaptopurine: Preclinical pharmacology, phase I/II trial, and pharmacokinetic study. Cancer Res 51:6079-6083.
2. Berns A, Rubenfeld S, Rymzo WT Jr and Calabro JJ (1972) Hazard of combining allopurinol and thiopurine. N Engl J Med 286:730-731.
3. Bronk JR, Lister N and Shaw MI (1988) Transport and metabolism of 6-thioguanine and 6-mercaptopurine in mouse small intestine. Clin Sci 74:629-638.
4. Brox L, Birkett L and Belch A (1981) Clinical pharmacology of oral thioguanine in acute myelogenous leukemia. Cancer Chemother Pharmacol 6:35-38.
5. Clarke DA, Elion GB, Hitchings GH and Stock CC (1958) Structure activity relationships among purines related to 6-marcaptopurine. Cancer Res 18:445-456.
6. Elion GB (1967) Biochemistry and pharmacology of purine analogues. Fed Proc 26:898-904.
7. Elion GB (1969) Actions of purine analogs: Enzyme specificity studies as a basis for interpretation and design. Cancer Res 29:2448-2453.
8. Elion GB (1989) The purine path to chemotherapy. Science 244:41-47.
9. Elion GB, Callahan S, Bieber S, Hitchings GH and Rundles RW (1961) A summary of investigations with 6-[(1-methyl-4-nitro-5-imidzolyl)thio]purine (BW 57-322). Cancer Chemother Rep 14:93-98.
10. Elion GB, Callahan S, Rundles RW and Hitchings GH (1963) Relationship between metabolic fates and antitumor activities of thiopurines. Cancer Res 23: 1207-1217.
11. Gee TS, Yu KP and Clarkson BD (1969) Treatment of adult acute leukemia with arabinosylcytosine and thioguanine. Cancer 23:1019-1032.
12. Hall WW and Krenitsky TA (1986) Aldehyde oxidase from rabbit liver: Specificity toward purines and their analogs. Arch Biochem Biophys 251:36-46.
13. Hamilton L and Elion GB (1954) The fate of 6-mercaptopurine in man. Ann NY Acad Sci 60:304-314.
14. Hande KR and Garrow GC (1996) Purine antimetabolites, in Cancer Chemotherapy and Biotherapy: Principles and Practice (Chabner BA and Longo DL eds) pp 235-252, Lippincott-Raven Publishers, Philadelphia.
15. Johns DG, Iannotti AT, Sartorelli AG and Bertino JR (1966) The relative toxicities of methotrexate and aminopterin. Biochem Pharmacol 15:555-561.
16. Johns DG and Loo TL (1967) Metabolite of 4-amino-4-deoxy-N10-methylpteroylglutamic acid (methotrexate). J Pharml Sci 56:356-359.
17. Keuzenkanvp-Jansen CW, Van Baal JM, De Abreu R, De Jong JGN, Zuiderent R and Trijbels JMF (1996) Detection and identification of 6-methylmercapto-8-hydroxypurine, a major metabolite of 6-mercaptopurine, in plasma during intra-venous administration. Clin Chem 42:380-386.
18. Kitchen BJ, Balis FM, Poplack DG, O'Brien M, Craig CE and Adamson PC (1997) A pediatric phase I trial and pharmacokinetic study of thioguanine administered by continuous i.v. infusion. Clin Cancer Res 3:713-717.
19. Konits PH, Egorin M, Van ED, Aisner J, Andrews PA, May ME, Bachur NR and Wiernik PH (1982) Phase II evaluation and plasma pharmacokinetics of high-dose intravenous 6-thioguanine in patients with colorectal carcinoma. Cancer Chemother Pharmacol 8:199-203.
20. Krenitsky TA, Neil SM, Elion GB and Hitchings GH (1972) A comparison of the specificities of xanthine oxidase and aldehyde oxidase. Arch Biochem Biophys 150:585-599.
21. Rundles RW, Wyngaarden JB, Hitchings GH, Elion GB and Silberman HR (1963) Effects of a xanthine oxidase inhibtor on thiopurine metabolism, hyperuricemia and gout. Trans Assoc Am Physicians 76:126-140.
22. Waddell WJ and Hill C (1956) A simple ultraviolet spectophotometric method for determination of protein. J Lab Clin Med 48:311-314.
23. Weinshilboum RM, Raymond FA and Pazmino PA (1978) Human erythrocyte thiopurine methyltransferase: Radiochemical microassay and biochemical properties. Clin Chim Acta 86:323-333.
24. Widemann BC, Hetherington ML, Murphy RF, Balis FM and Adamson PC (1995) Carboxypeptidase-G2 rescue in a patient with high dose methotrexate-induced nephrotoxicity. Cancer 76:521-526.
25. Zimm S, Collins JM, O'Neill D, Chabner BA and Poplack DG (1983a) Inhibition of first-pass metabolism in cancer chemotherapy: Interaction of 6-mercaptopurine and allopurinol. Clin Pharmacol Ther 34:810-817.
26. Zimm S, Collins JM, Riccardi R, O'Neill D, Narang PK, Chabner B and Poplack DG (1983b) Variable bioavailability of oral mercaptopurine. Is maintenance chemotherapy in acute lymphoblastic leukemia being optimally delivered? N Engl J Med 308:1005-1009.
27. Zimm S, Grygiel JJ, Strong JM, Monks TJ and Poplack DG (1984) Identification of 6-mercaptopurine riboside in patients receiving 6-mercaptopurine as a prolonged intravenous infusion. Biochem Pharmacol 33:4089-4092.